Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$65.28 +0.7%	$60.97	$43.70 ▼ $86.53	$2.08B	-1.44	48,432 shs	8,868 shs
HRMY Harmony Biosciences	$35.16 -0.4%	$31.67	$26.47 ▼ $41.61	$2.02B	0.87	610,732 shs	646,693 shs
NAMS NewAmsterdam Pharma	$19.39 +3.7%	$17.76	$14.06 ▼ $27.29	$2.18B	0.01	653,808 shs	1.31 million shs
STOK Stoke Therapeutics	$10.94 +0.4%	$8.58	$5.35 ▼ $17.58	$597.29M	1.2	702,319 shs	598,670 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	+0.71%	+5.96%	+4.45%	+6.91%	+33.88%
HRMY Harmony Biosciences	-0.42%	+4.27%	+17.36%	+4.30%	+18.34%
NAMS NewAmsterdam Pharma	+3.75%	+12.02%	-4.20%	-17.49%	+2.81%
STOK Stoke Therapeutics	+0.37%	+16.01%	+12.78%	+34.23%	-31.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLTE Belite Bio	2.0426 of 5 stars	3.5	3.0	0.0	1.3	0.8	0.6
HRMY Harmony Biosciences	4.947 of 5 stars	4.6	4.0	0.0	3.5	3.3	4.4
NAMS NewAmsterdam Pharma	2.7312 of 5 stars	3.5	1.0	0.0	2.7	5.0	0.0
STOK Stoke Therapeutics	3.9666 of 5 stars	3.6	2.0	4.8	2.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLTE Belite Bio	3.00	Buy	$96.67	48.08% Upside
HRMY Harmony Biosciences	3.11	Buy	$53.00	50.74% Upside
NAMS NewAmsterdam Pharma	3.00	Buy	$42.86	121.03% Upside
STOK Stoke Therapeutics	3.29	Buy	$23.20	112.07% Upside

Current Analyst Ratings Breakdown

Latest STOK, NAMS, BLTE, and HRMY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/4/2025	NAMS NewAmsterdam Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$42.00
6/2/2025	HRMY Harmony Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$61.00
5/15/2025	BLTE Belite Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/15/2025	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00
5/15/2025	HRMY Harmony Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$44.00 ➝ $48.00
5/14/2025	STOK Stoke Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/14/2025	STOK Stoke Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$47.00 ➝ $35.00
5/13/2025	HRMY Harmony Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/8/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$42.00 ➝ $40.00
5/6/2025	HRMY Harmony Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$49.00 ➝ $49.00
4/28/2025	HRMY Harmony Biosciences	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $48.00

(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLTE Belite Bio	N/A	N/A	N/A	N/A	$3.28 per share	N/A
HRMY Harmony Biosciences	$744.85M	2.71	$2.63 per share	13.38	$7.97 per share	4.41
NAMS NewAmsterdam Pharma	$47.14M	46.18	N/A	N/A	$3.50 per share	5.54
STOK Stoke Therapeutics	$190.91M	3.13	N/A	N/A	$3.57 per share	3.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLTE Belite Bio	-$31.63M	-$1.36	N/A	N/A	N/A	N/A	-31.94%	-30.73%	8/8/2025 (Estimated)
HRMY Harmony Biosciences	$128.85M	$2.62	16.66	11.31	0.47	17.98%	23.16%	14.24%	8/5/2025 (Estimated)
NAMS NewAmsterdam Pharma	-$176.94M	-$1.88	N/A	N/A	N/A	N/A	N/A	N/A	8/6/2025 (Estimated)
STOK Stoke Therapeutics	-$104.70M	$0.79	N/A	N/A	N/A	-629.90%	-54.45%	-40.77%	8/5/2025 (Estimated)

Latest STOK, NAMS, BLTE, and HRMY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	NAMS NewAmsterdam Pharma	-$0.45	-$0.49	-$0.04	-$0.34	$1.46 million	$2.98 million
5/6/2025	Q1 2025	HRMY Harmony Biosciences	$0.59	$0.78	+$0.19	$0.78	$184.26 million	$184.73 million
3/24/2025	Q4 2024	STOK Stoke Therapeutics	-$0.56	-$0.18	+$0.38	-$0.18	$4.20 million	$22.61 million
3/17/2025	Q4 2024	BLTE Belite Bio	-$0.30	-$0.32	-$0.02	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLTE Belite Bio	N/A	30.73	30.73
HRMY Harmony Biosciences	0.28	3.24	3.20
NAMS NewAmsterdam Pharma	N/A	10.61	10.61
STOK Stoke Therapeutics	N/A	5.09	5.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLTE Belite Bio	0.53%
HRMY Harmony Biosciences	86.23%
NAMS NewAmsterdam Pharma	89.89%
STOK Stoke Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
BLTE Belite Bio	13.29%
HRMY Harmony Biosciences	23.60%
NAMS NewAmsterdam Pharma	20.84%
STOK Stoke Therapeutics	11.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLTE Belite Bio	10	31.84 million	27.61 million	Not Optionable
HRMY Harmony Biosciences	200	57.42 million	39.47 million	Optionable
NAMS NewAmsterdam Pharma	4	112.27 million	74.37 million	Optionable
STOK Stoke Therapeutics	100	54.60 million	46.98 million	Optionable

STOK, NAMS, BLTE, and HRMY Headlines

Recent News About These Companies

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Recommendation of "Buy" from Analysts

June 5 at 1:48 AM | marketbeat.com

Stoke Therapeutics (NASDAQ:STOK) Trading 10.3% Higher - Here's Why

June 4 at 4:52 PM | marketbeat.com

BNP Paribas Financial Markets Trims Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)

June 4 at 3:24 AM | marketbeat.com

Financial Review: Renovaro (NASDAQ:RENB) & Stoke Therapeutics (NASDAQ:STOK)

June 2 at 2:25 AM | americanbankingnews.com

Voloridge Investment Management LLC Sells 36,261 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 31, 2025 | marketbeat.com

Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference

May 29, 2025 | businesswire.com

D. E. Shaw & Co. Inc. Sells 143,203 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 29, 2025 | marketbeat.com

Toronto Dominion Bank Invests $35 Million in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 28, 2025 | marketbeat.com

Biogen maps out $1B biobucks deal with RNAi-focused City Therapeutics

May 27, 2025 | fiercebiotech.com

Deutsche Bank AG Reduces Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 22, 2025 | marketbeat.com

Toronto Dominion Bank Acquires New Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 21, 2025 | marketbeat.com

Tang Capital Management LLC Buys Shares of 300,000 Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 20, 2025 | marketbeat.com

Chardan Capital Has Strong Forecast for STOK FY2025 Earnings

May 20, 2025 | marketbeat.com

RTW Investments LP Has $56.51 Million Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 18, 2025 | marketbeat.com

Stoke Therapeutics (NASDAQ:STOK) Upgraded to Strong-Buy at Cantor Fitzgerald

May 17, 2025 | marketbeat.com

Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet

May 16, 2025 | zacks.com

MPM Bioimpact LLC Has $7.57 Million Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 16, 2025 | marketbeat.com

Stoke Therapeutics (NASDAQ:STOK) Shares Gap Up Following Earnings Beat

May 15, 2025 | marketbeat.com

Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates

May 13, 2025 | zacks.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Purchased by Dimensional Fund Advisors LP

May 13, 2025 | marketbeat.com

Granahan Investment Management LLC Trims Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 12, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

STOK, NAMS, BLTE, and HRMY Company Descriptions

Belite Bio NASDAQ:BLTE

$65.28 +0.46 (+0.71%)

As of 06/4/2025 04:00 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Harmony Biosciences NASDAQ:HRMY

$35.16 -0.15 (-0.42%)

Closing price 06/4/2025 04:00 PM Eastern

Extended Trading

$35.50 +0.34 (+0.97%)

As of 08:00 AM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

NewAmsterdam Pharma NASDAQ:NAMS

$19.39 +0.70 (+3.75%)

As of 06/4/2025 04:00 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Stoke Therapeutics NASDAQ:STOK

$10.94 +0.04 (+0.37%)

Closing price 06/4/2025 04:00 PM Eastern

Extended Trading

$11.05 +0.11 (+1.01%)

As of 08:00 AM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time